Biogen has announced that
its long-acting factor product
Eloctate (efmoroctocog alfa) is now
indicated for use in patients under
the age of 12 with haemophilia A
(congenital factor VIII deficiency).
Approximately 2,200 Australians
have haemophilia A - including an
estimated 350 under the age of
12 years.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jun 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.